UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Case Report: Significant Clinical Benefit From Pemetrexed-Based Therapy in ROS1- and ALK-rearranged Lung Cancer With Adenosquamous Histology

Frontiers in oncology, 2022-01, Vol.11, p.788245

2022

Volltextzugriff (PDF)

Abstract 1375: Activity of pemetrexed in patients with driver oncogene positive non-small cell lung cancer and squamous histology

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.1375-1375

2021

Volltextzugriff (PDF)

Implementing personalized lung cancer care with spatial profiling, patient derived organoids, and rationally designed drug testing

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.e20521-e20521

2024

Volltextzugriff (PDF)

Phase 1/2 trial of the XPO1 inhibitor selinexor in combination with docetaxel in previously treated, advanced KRAS mutant non-small cell lung cancer (NSCLC)

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.8597-8597

2024

Volltextzugriff (PDF)

Improving diversity in phase I oncology clinical trials: A single institution experience at the University of Colorado Cancer Center

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.e13687-e13687

2024

Volltextzugriff (PDF)

High PD-L1 expression among patients with ALK rearranged non–small cell lung cancer and response to first line ALK tyrosine kinase inhibitors

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.8626-8626

2024

Volltextzugriff (PDF)

Telisotuzumab vedotin monotherapy in patients with previously treated c-Met–overexpressing non-squamous EGFR wildtype advanced NSCLC: Primary analysis of the LUMINOSITY trial

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.103-103

2024

Volltextzugriff (PDF)

Repotrectinib in tyrosine kinase inhibitor (TKI)-naïve patients (pts) with advanced ROS1 fusion-positive ( ROS1+) NSCLC in the phase 1/2 TRIDENT-1 trial: Clinical update, treatment beyond progression and subsequent therapies

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.8522-8522

2024

Volltextzugriff (PDF)

Association of RNA-sequencing signatures with clinical outcomes of pembrolizumab + chemotherapy in patients with metastatic nonsquamous non–small cell lung cancer (NSCLC) enrolled in the phase 2 KEYNOTE-782 trial

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.8578-8578

2024

Volltextzugriff (PDF)

Dr. David Ross Camidge: always be the first to see something

Translational lung cancer research, 2018-02, Vol.7 (S1), p.S70-S71

2018

Volltextzugriff (PDF)

GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients

Lung cancer (Amsterdam, Netherlands), 2020-10, Vol.148, p.48-54

2020

Volltextzugriff (PDF)

A phase 2, open-label, multi-center study of amuvatinib in combination with platinum etoposide chemotherapy in platinum-refractory small cell lung cancer patients

Oncotarget, 2017-10, Vol.8 (46), p.81441-81454

2017

Volltextzugriff (PDF)

Anti-ALK Antibodies in Patients with ALK-Positive Malignancies Not Expressing NPM-ALK

Journal of Cancer, 2016-01, Vol.7 (11), p.1383-1387

2016

Volltextzugriff (PDF)

Case Report: Significant Clinical Benefit From Pemetrexed-Based Therapy in ROS1- and ALK-rearranged Lung Cancer With Adenosquamous Histology

Frontiers in oncology, 2021, Vol.11, p.788245-788245

2021

Volltextzugriff (PDF)

Studies on the adaptors of clathrin-coated vesicles

Camidge, David Ross

1992

Volltextzugriff (PDF)

Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials

Journal of clinical oncology, 2018-09, Vol.36 (26), p.2693-2701

2018

Volltextzugriff (PDF)

Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations

Cancer discovery, 2018-10, Vol.8 (10), p.1227-1236

2018

Volltextzugriff (PDF)

Short communication: The activity of brigatinib in patients with disease progression after next generation anaplastic lymphoma tyrosine kinase inhibitors and an exploratory analysis of circulating tumor DNA

Lung cancer (Amsterdam, Netherlands), 2022-03, Vol.165, p.43-48

2022

Volltextzugriff (PDF)

The Role of Local Therapy for Oligo-Progressive Disease in Oncogene-Addicted Non-Small-Cell Lung Cancer

Advances in radiation oncology, 2024-07, Vol.9 (7), p.101516, Article 101516

2024

Volltextzugriff (PDF)

Real-world insights into patients with advanced NSCLC and MET alterations

Lung cancer (Amsterdam, Netherlands), 2021-09, Vol.159, p.96-106

2021

Volltextzugriff (PDF)

O7-4 Phase 1b efficacy of telisotuzumab vedotin and osimertinib in Asian vs non-Asian patients with advanced NSCLC

Annals of oncology, 2023-11, Vol.34, p.S1387-S1387

2023

Volltextzugriff (PDF)

Abstract P048: A phase 2 study of VS-6766 (dual RAF/MEK inhibitor) RAMP 202, as a single agent and in combination with defactinib (FAK inhibitor) in recurrent KRAS-mutant (KRAS-MT) non-small cell lung cancer (NSCLC)

Molecular cancer therapeutics, 2021-12, Vol.20 (12_Supplement), p.P048-P048

2021

Volltextzugriff (PDF)

A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC

JTO clinical and research reports, 2022-01, Vol.3 (1), p.100262-100262, Article 100262

2022

Volltextzugriff (PDF)

Phase 1/1b study of telisotuzumab vedotin (Teliso-V) + osimertinib (Osi), after failure on prior Osi, in patients with advanced, c-Met overexpressing, EGFR -mutated non-small cell lung cancer (NSCLC)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.9013-9013

2022

Volltextzugriff (PDF)

1 – 25 von 88

Suche als RSS-Feed

Aktive Filter

ThemaHumans

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(82)
Mit Volltextzugriff
(76)

Publikationsform

Sprache

Englisch
(88)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(7)

Menü

Weitere Dienste

Einstellungen

Case Report: Significant Clinical Benefit From Pemetrexed-Based Therapy in ROS1- and ALK-rearranged Lung Cancer With Adenosquamous Histology

Abstract 1375: Activity of pemetrexed in patients with driver oncogene positive non-small cell lung cancer and squamous histology

Implementing personalized lung cancer care with spatial profiling, patient derived organoids, and rationally designed drug testing

Phase 1/2 trial of the XPO1 inhibitor selinexor in combination with docetaxel in previously treated, advanced KRAS mutant non-small cell lung cancer (NSCLC)

Improving diversity in phase I oncology clinical trials: A single institution experience at the University of Colorado Cancer Center

High PD-L1 expression among patients with ALK rearranged non–small cell lung cancer and response to first line ALK tyrosine kinase inhibitors

Telisotuzumab vedotin monotherapy in patients with previously treated c-Met–overexpressing non-squamous EGFR wildtype advanced NSCLC: Primary analysis of the LUMINOSITY trial

Repotrectinib in tyrosine kinase inhibitor (TKI)-naïve patients (pts) with advanced ROS1 fusion-positive ( ROS1+) NSCLC in the phase 1/2 TRIDENT-1 trial: Clinical update, treatment beyond progression and subsequent therapies

Association of RNA-sequencing signatures with clinical outcomes of pembrolizumab + chemotherapy in patients with metastatic nonsquamous non–small cell lung cancer (NSCLC) enrolled in the phase 2 KEYNOTE-782 trial

Dr. David Ross Camidge: always be the first to see something

GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients

A phase 2, open-label, multi-center study of amuvatinib in combination with platinum etoposide chemotherapy in platinum-refractory small cell lung cancer patients

Anti-ALK Antibodies in Patients with ALK-Positive Malignancies Not Expressing NPM-ALK

Case Report: Significant Clinical Benefit From Pemetrexed-Based Therapy in ROS1- and ALK-rearranged Lung Cancer With Adenosquamous Histology

Studies on the adaptors of clathrin-coated vesicles

Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials

Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations

Short communication: The activity of brigatinib in patients with disease progression after next generation anaplastic lymphoma tyrosine kinase inhibitors and an exploratory analysis of circulating tumor DNA

The Role of Local Therapy for Oligo-Progressive Disease in Oncogene-Addicted Non-Small-Cell Lung Cancer

Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein–Overexpressing Advanced Nonsquamous EGFR -Wildtype Non–Small Cell Lung Cancer in the Phase II LUMINOSITY Trial

Real-world insights into patients with advanced NSCLC and MET alterations

O7-4 Phase 1b efficacy of telisotuzumab vedotin and osimertinib in Asian vs non-Asian patients with advanced NSCLC

Abstract P048: A phase 2 study of VS-6766 (dual RAF/MEK inhibitor) RAMP 202, as a single agent and in combination with defactinib (FAK inhibitor) in recurrent KRAS-mutant (KRAS-MT) non-small cell lung cancer (NSCLC)

A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC

Phase 1/1b study of telisotuzumab vedotin (Teliso-V) + osimertinib (Osi), after failure on prior Osi, in patients with advanced, c-Met overexpressing, EGFR -mutated non-small cell lung cancer (NSCLC)

Aktive Filter

Suchergebnisse filtern